Additional Member for the Board of Directors of Bachem Holding AG
Bachem (SIX: BANB) has announced that Dr. Simone Wyss Fedele will be recommended for election to the Board of Directors at the Annual General Meeting on April 30, 2025. Dr. Wyss Fedele, currently CEO of Switzerland Global Enterprise (S-GE), brings extensive experience in the life science industry and international business.
Dr. Wyss Fedele's background includes leadership roles at Novartis International as Chief Economist and Head of Public Affairs, and at Takeda Pharmaceuticals as Commercial Lead and Head of Market Access for Europe and Canada. She holds positions on various prestigious boards, including the WEF Global Future Councils and the Swiss National Bank's Regional Council Northwest Switzerland.
All current board members will stand for re-election. The company has also announced key upcoming dates, including the dividend payout date on May 7, 2025, and the Half-Year Report 2025 publication on July 24, 2025.
Bachem (SIX: BANB) ha annunciato che il Dr. Simone Wyss Fedele sarà raccomandato per l'elezione al Consiglio di Amministrazione durante l'Assemblea Generale Annuale del 30 aprile 2025. Il Dr. Wyss Fedele, attualmente CEO di Switzerland Global Enterprise (S-GE), porta con sé una vasta esperienza nel settore delle scienze della vita e negli affari internazionali.
Il background del Dr. Wyss Fedele include ruoli di leadership presso Novartis International come Economista Capo e Responsabile delle Relazioni Pubbliche, e presso Takeda Pharmaceuticals come Responsabile Commerciale e Capo dell'Accesso al Mercato per Europa e Canada. Ricopre anche posizioni in vari consigli prestigiosi, tra cui i Consigli Globali del Futuro del WEF e il Consiglio Regionale della Banca Nazionale Svizzera per la Svizzera Nordoccidentale.
Tutti gli attuali membri del consiglio si ricandideranno. L'azienda ha anche annunciato date chiave in arrivo, tra cui la data di pagamento del dividendo il 7 maggio 2025 e la pubblicazione del Rapporto Semestrale 2025 il 24 luglio 2025.
Bachem (SIX: BANB) ha anunciado que el Dr. Simone Wyss Fedele será recomendado para su elección al Consejo de Administración en la Junta General Anual el 30 de abril de 2025. El Dr. Wyss Fedele, actualmente CEO de Switzerland Global Enterprise (S-GE), aporta una amplia experiencia en la industria de ciencias de la vida y en negocios internacionales.
El historial del Dr. Wyss Fedele incluye roles de liderazgo en Novartis International como Economista Jefe y Jefe de Asuntos Públicos, y en Takeda Pharmaceuticals como Líder Comercial y Jefe de Acceso al Mercado para Europa y Canadá. También ocupa posiciones en varios consejos prestigiosos, incluidos los Consejos Globales del Futuro del WEF y el Consejo Regional del Banco Nacional Suizo para Suiza del Noroeste.
Todos los miembros actuales del consejo se presentarán a la reelección. La empresa también ha anunciado fechas clave próximas, incluida la fecha de pago del dividendo el 7 de mayo de 2025 y la publicación del Informe Semestral 2025 el 24 de julio de 2025.
바켐 (SIX: BANB)은 드. 시몬 와이스 페델이 2025년 4월 30일 연례 총회에서 이사회 선출을 위해 추천될 것이라고 발표했습니다. 드. 와이스 페델은 현재 스위스 글로벌 기업(S-GE)의 CEO로, 생명 과학 산업과 국제 비즈니스에서 폭넓은 경험을 가지고 있습니다.
드. 와이스 페델의 경력에는 노바티스 인터내셔널에서 수석 경제학자 및 공공 업무 책임자로, 타케다 제약에서 유럽 및 캐나다 시장 접근 책임자 및 상업 책임자로서의 리더십 역할이 포함됩니다. 그녀는 WEF 글로벌 미래 위원회 및 스위스 중앙은행 북서부 스위스 지역 위원회 등 여러 권위 있는 이사회에서 활동하고 있습니다.
현재 이사회 구성원 모두가 재선에 나설 것입니다. 회사는 또한 2025년 5월 7일 배당금 지급일과 2025년 7월 24일 반기 보고서 발표와 같은 주요 예정 날짜를 발표했습니다.
Bachem (SIX: BANB) a annoncé que Dr. Simone Wyss Fedele sera recommandée pour l'élection au Conseil d'Administration lors de l'Assemblée Générale Annuelle le 30 avril 2025. Dr. Wyss Fedele, actuellement PDG de Switzerland Global Enterprise (S-GE), possède une vaste expérience dans l'industrie des sciences de la vie et dans les affaires internationales.
Le parcours de Dr. Wyss Fedele comprend des postes de direction chez Novartis International en tant qu'Économiste en Chef et Responsable des Affaires Publiques, et chez Takeda Pharmaceuticals en tant que Responsable Commercial et Responsable de l'Accès au Marché pour l'Europe et le Canada. Elle occupe également des postes au sein de divers conseils prestigieux, notamment les Conseils Mondiaux du Futur du WEF et le Conseil Régional de la Banque Nationale Suisse pour la Suisse Nord-Ouest.
Tous les membres actuels du conseil se représenteront. L'entreprise a également annoncé des dates clés à venir, y compris la date de paiement du dividende le 7 mai 2025 et la publication du Rapport Semestriel 2025 le 24 juillet 2025.
Bachem (SIX: BANB) hat bekannt gegeben, dass Dr. Simone Wyss Fedele für die Wahl in den Verwaltungsrat bei der Hauptversammlung am 30. April 2025 empfohlen wird. Dr. Wyss Fedele, derzeit CEO von Switzerland Global Enterprise (S-GE), bringt umfangreiche Erfahrung in der Lebenswissenschaftsbranche und im internationalen Geschäft mit.
Der Hintergrund von Dr. Wyss Fedele umfasst Führungspositionen bei Novartis International als Chefökonomin und Leiterin der Öffentlichkeitsarbeit sowie bei Takeda Pharmaceuticals als kommerzielle Leitung und Leiterin des Marktzugangs für Europa und Kanada. Sie hat Positionen in verschiedenen angesehenen Gremien inne, darunter die Global Future Councils des WEF und der Regionalrat der Schweizerischen Nationalbank für die Nordwestschweiz.
Alle derzeitigen Vorstandsmitglieder werden zur Wiederwahl antreten. Das Unternehmen hat auch wichtige bevorstehende Termine bekannt gegeben, darunter das Datum der Dividendenausschüttung am 7. Mai 2025 und die Veröffentlichung des Halbjahresberichts 2025 am 24. Juli 2025.
- Addition of board member with extensive life science industry experience and international network
- New director brings strong pharmaceutical industry background from Novartis and Takeda
- Stability indicated by all current board members standing for re-election
- None.
Bubendorf, Switzerland--(Newsfile Corp. - April 3, 2025) - Bachem (SIX: BANB) announced today that the Board of Directors will recommend the election of Dr. Simone Wyss Fedele, CEO of Switzerland Global Enterprise, to the Annual General Meeting on April 30, 2025. All current members of the Board of Directors will stand for re-election.
Dr. Kuno Sommer, Chairman of the Board of Directors, remarked: “I am very pleased that we can propose a leader like Simone Wyss Fedele for election as a new member of the Board of Directors. She has an excellent track record in the life science industry and an outstanding international network."
Simone Wyss Fedele has been CEO of Switzerland Global Enterprise (S-GE), the official Swiss organization for export and investment promotion, since 2019, where she intermittently also held the role of CFO. She is designated for the chairmanship of the S-GE Board of Directors and is currently a member of the WEF Global Future Councils on International Trade and Investment.
Simone Wyss Fedele has held leadership positions in a wide range of industries for over two decades. She was Chief Economist and Head of Public Affairs at Novartis International in Switzerland and a member of the Swiss Country Executive Team. Prior to that, she was Commercial Lead and Head of Market Access for Europe and Canada at Takeda Pharmaceuticals. Simone Wyss Fedele is a member of the Regional Council Northwest Switzerland of the Swiss National Bank, the Executive Committee of the Swiss Institute for International Economics and Applied Economic Research at the University of St. Gallen, and the Advisory Board of the International Trade Center. She holds a doctorate in international economics from the University of Basel and has extensive management and board experience.
Financial Calendar
April 30, 2025 Annual General Meeting (business year 2024)
May 7, 2025 Payout date for dividend
July 24, 2025 Publication of Half-Year Report 2025
March 12, 2026 Publication of Annual Report 2025; Media and Analyst conference
About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with its headquarters in Switzerland and sites in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.
For more information:
Media
Dr. Daniel Grotzky
Head Group Communications
Tel.: +41 58 595 2021
Email: media@bachem.com
Investors
Barbora Blaha
Head Investor Relations
Tel.: +41 58 595 0573
Email: ir@bachem.com
This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Bachem Holding AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Bachem Holding AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247218
FAQ
When will Dr. Simone Wyss Fedele join Bachem's Board of Directors?
What is Dr. Simone Wyss Fedele's current role before joining Bachem's board?
What relevant experience does Dr. Wyss Fedele bring to Bachem's board?
When is Bachem's next dividend payout date?
